Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening

Area of Science:

• Biomedical Engineering
• Cancer Immunology
• Preclinical Oncology Models

Background:

• Current cancer immunotherapy research is limited by preclinical models lacking disease reproducibility and the ability to modulate tumor immune microenvironments.
• Existing models struggle to replicate the diverse immune landscapes observed in human tumors, hindering the development of effective immunotherapies.
• The inability to easily manipulate the tumor microenvironment complicates drug screening and testing workflows.

Purpose of the Study:

• To develop an improved preclinical platform for immune oncology drug development.
• To engineer biomaterial scaffolds that enhance tumor formation and reduce variability in preclinical models.
• To create tunable tumor immune microenvironments for more relevant immunotherapy testing.

Main Methods:

• Utilized engineered biomaterials as scaffolds for murine mammary carcinoma cell lines implanted into syngeneic mice.
• Modified synthetic gel formulations to reshape infiltrating immune cells within the tumor microenvironment.
• Tested the responsiveness of these engineered models to different cancer immunotherapies, including in situ vaccination and immune checkpoint blockade.

Main Results:

• Engineered biomaterials increased tumor formation rates and decreased disease latency.
• The biomaterial scaffolds diminished variability in immune cell infiltrates within tumors.
• Altering the synthetic gel formulations led to divergent responses to immunotherapies within the same tumor model.
• Demonstrated that the local immune microenvironment significantly influences immunotherapeutic response.

Conclusions:

• Engineered tumor immune microenvironments provide a more robust and reproducible preclinical platform for cancer immunotherapy research.
• This approach addresses limitations of current breast tumor models, enabling more relevant drug screening.
• The findings highlight the critical role of the tumor immune microenvironment in immunotherapy resistance and efficacy.
• The developed platform facilitates immunotherapeutic testing that reflects the variability seen in human patients.